Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients

  • STATUS
    Recruiting
  • participants needed
    60
  • sponsor
    Kafrelsheikh University
Send
Updated on 23 September 2024
See if I qualify

Summary

The aim of this study is to explore the effect of SGLT2i on the levels of cardiac biomarkers, inflammatory and stress markers in Egyptian heart failure patients to provide a better understanding of mechanism that might assist in tailoring treatment strategies in patients with various forms of HF especially in Egyptian population. Also understand how biomarkers may be employed to predict risk in patients receiving SGLT2i or identification of those who may derive the most benefit from SGLT2i in the means of individualized medicine.

Details
Condition Heart Failure
Age 18years - 80years
Clinical Study IdentifierNCT06585761
SponsorKafrelsheikh University
Last Modified on23 September 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Patients aged more than 18 years old
Patients are with cardiac function was graded as II-IV by the New York Heart Association (NYHA)
Patients are on standard therapy for management of HF (according to AHA/ACC/HFSA Guideline for the Management of Heart Failure2022)21 such as
ACEi (angiotensin converting enzyme inhibitor)
ARB (angiotensin receptor blocker)
ARNI in place of ACEi OR ARB
Beta blocker
(MRA) Mineralocorticoid receptor antagonists
Diuretics as needed
All patients signed the informed consent

Exclusion Criteria

Patients suffering from conditions like acute CVS illness and severe sepsis that raise inflammatory markers and may lead to cardiac dysfunction as opposed to heart failure
Patients with various cardiac conditions, such as severe congenital heart disease, myocarditis, and valvular heart disease
Female patients during pregnancy or lactation
Individuals suffering from a malignant tumor, hyperfunctioning thyroid, multiple organ failure, or significantly reduced kidney function (eGFR <20 mL/min/1.73 m²)
Individuals suffering from verbal communication disorders or psychic cognitive impairment
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.